Antibodies reactive with B7-H3 and users thereof
The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
1. A method of detecting the presence or absence of a cancer cell in a subject, comprising:
contacting cells from said subject with a polypeptide comprising the amino acid sequence of SEQ ID NO: 117 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 119; and
detecting a complex of B7-H3 from said cells and said polypeptides, if any, wherein said cancer cell expresses B7-H3.
2. The method of claim 1 , wherein said polypeptides bind to B7-H3 that is endogenously expressed on the surface of said cancer cell.
3. The method of claim 1 , wherein said cancer cell is selected from the group consisting of a cancer cell of a bladder cancer, a cervical cancer, a colon cancer, a colorectal cancer, a gastric cancer, a liver cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a kidney cancer, a breast cancer, a head and neck cancer, a skin cancer, a sarcoma, a brain tumor, a brain and spinal cord cancer, an adrenal cancer, a uterine cancer, a neuroblastoma, a small round cell tumor, a peripheral nerve sheath tumor, a bone cancer, a rhabdoid tumor, a lymphoma, a multiple myeloma, a leukemia, a neuroendocrine tumor, and a melanoma.
4. The method of claim 1 , wherein said polypeptides are an antibody.
5. The method of claim 4 , wherein said antibody is a humanized antibody or a chimeric antibody.
6. The method of claim 4 , wherein said antibody is a monoclonal antibody or a bispecific antibody.
7. A diagnostic system for detecting B7-H3 expressed by a cancer cell in a sample, said diagnostic system comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 117 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 119.
8. The diagnostic system of claim 7 , wherein said polypeptides are an antibody.
9. The diagnostic system of claim 8 , wherein said antibody is a humanized antibody or a chimeric antibody.
10. The diagnostic system of claim 8 , wherein said antibody is a monoclonal antibody or a bispecific antibody.
11. The diagnostic system of claim 7 , wherein said sample comprises a bodily fluid selected from the group consisting of blood, saliva, urine, pulmonary fluid, or ascites fluid.
12. The diagnostic system of claim 7 , wherein said sample comprises a tissue sample selected from the group consisting of ovary tissue, breast tissue, lung tissue, prostate tissue, colon tissue, cervical tissue, kidney tissue, skin tissue, thyroid tissue, brain tissue, heart tissue, liver tissue, stomach tissue, nerve tissue, blood vessel tissue, bone tissue, upper digestive tract tissue, and pancreas tissue.
13. The diagnostic system of claim 7 , further comprising a detectable label conjugated to at least one of said polypeptides.
14. A pharmaceutical composition for diagnosing or monitoring a disease or disorder in a subject, said composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 117 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 119.
15. The pharmaceutical composition of claim 14 , wherein said polypeptides are an antibody.
16. The pharmaceutical composition of claim 15 , wherein said antibody is a humanized antibody or a chimeric antibody.
17. The pharmaceutical composition of claim 15 , wherein said antibody is a monoclonal antibody or a bispecific antibody.
18. The pharmaceutical composition of claim 14 , wherein said disease or disorder is an inflammatory or autoimmune disease or disorder.
19. The pharmaceutical composition of claim 14 , wherein said disease or disorder is cancer.
20. The pharmaceutical composition of claim 19 , wherein said cancer is selected from the group consisting of a bladder cancer, a cervical cancer, a colon cancer, a colorectal cancer, a gastric cancer, a liver cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a kidney cancer, a breast cancer, a head and neck cancer, a skin cancer, a sarcoma, a brain tumor, a brain and spinal cord cancer, an adrenal cancer, a uterine cancer, a neuroblastoma, a small round cell tumor, a peripheral nerve sheath tumor, a bone cancer, a rhabdoid tumor, a lymphoma, a multiple myeloma, a leukemia, a neuroendocrine tumor, and a melanoma.